Camp4 Therapeutics Corp (CAMP) Stock Price, Quote & News

Company Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8867

Website: www.camp4tx.com

Address:

One Kendall Square, 3rd Floor Building 1400 West, Cambridge, United States

TigrePeidando Jul. 9 at 3:57 PM

https://www.marketbeat.com/instant-alerts/camp4-therapeutics-nasdaqcamp-upgraded-to-strong-buy-at-rodman-renshaw-2026-04-15/ Anticipating $NVDA expanding deeper into their AI-powered drug discovery and precision medicine. $CAMP could be in a great position to benefit from that broader trend. Strong buy due to the AI-driven RNA platform angle 🚀🚀🚀🚀🚀🚀

0 · Reply

5G_C Jul. 9 at 1:26 PM

Comparing $CAMP to names like $NVVE or $VTAK, I think $CAMP has the more compelling long-term speculative setup. Unlike those companies, $CAMP combines an AI-driven RNA discovery platform and has a strategic GSK collaboration, giving it multiple ways to create value. When AI becomes a major catalyst in biotech over the next few years, I believe CAMP's upside could be even greater than what we've seen from those names. I think $20+ is possible and potentially higher when partnerships announced 🚀🚀🚀

0 · Reply

5G_C Jul. 9 at 11:15 AM

$CAMP $NVDA partnership to be announced later this month 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

5G_C Jul. 9 at 11:09 AM

$NVDA $CAMP

0 · Reply

TigrePeidando Jul. 9 at 11:05 AM

$CAMP has the stronger AI structure vs $VTAK While $VTAK pushes AI aviation via Flyte, CAMP’s RNA platform uses advanced AI-driven modeling for precise gene expression fixes in genetic disorders with solid efficacy data and growing patient pipeline. Way more bullish on $CAMP focused biotech AI edge.

0 · Reply

ZinoStonks Jul. 9 at 3:10 AM

$CAMP is transforming from a tiny biotech into an AI-powered precision medicine company. When Anthropic partnership happens, the upside will be enormous. Add a cash runway through 2038, advancing SYNGAP1 progress, the GSK partnership, and RAP/EPIC AI, and there are multiple potential catalysts ahead. Positive data, new partnerships, and AI news could drive major momentum. $20+ possible if several catalysts align. This is giving $NVVE, $VTAK, and $TVRD style momentum. 🚀🚀🚀

1 · Reply

Revicta Jul. 2 at 2:37 AM

$CAMP consolidating back to $4

0 · Reply

TigrePeidando Jul. 1 at 2:05 PM

$CAMP Feels like something great is going to happen soon 🚀🚀🚀🚀

0 · Reply

Revicta Jun. 29 at 1:25 PM

$CAMP today we may push to $5++++

0 · Reply

5G_C Jun. 29 at 9:50 AM

$NVDA could partner with $CAMP to expand its AI medicine tools. Buying more now, should see $20+ within the next couple of months! 🚀 📈

0 · Reply

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

XFOR

Jun 19, 2026, 4:05 PM EDT - 25 days ago

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-16T09:40:29.000Z - 4 weeks ago

Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan

Jun 10, 2026, 11:00 AM EDT - 4 weeks ago

Camp4 Therapeutics Transcript: AGM 2026

2026-06-10T08:20:08.000Z - 5 weeks ago

Camp4 Therapeutics initiated with a Buy at Chardan

Jun 8, 2026, 6:30 AM EDT - 5 weeks ago

New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity

May 21, 2026, 4:05 PM EDT - 7 weeks ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026, 7:00 AM EDT - 2 months ago

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

2026-05-07T22:28:59.000Z - 2 months ago

Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)

May 7, 2026, 4:05 PM EDT - 2 months ago

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

May 7, 2026, 7:00 AM EDT - 2 months ago

Camp4 Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Camp4 Therapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Camp4 Therapeutics Proxy statement: Proxy filing

2026-04-14T10:54:06.000Z - 3 months ago

Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw

Apr 13, 2026, 12:45 PM EDT - 3 months ago

Camp4 Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-02T10:11:49.000Z - 3 months ago

Camp4 Therapeutics price target raised to $9 from $8 at Leerink

Mar 24, 2026, 7:00 AM EDT - 4 months ago

CAMP4 Appoints Michael MacLean to its Board of Directors

Mar 17, 2026, 10:00 AM EDT - 4 months ago

Camp4 Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

2026-03-12T16:00:19.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

SPRB

2026-03-11T16:25:40.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Mar 9, 2026, 8:40 AM EDT - 4 months ago

Camp4 Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 4:05 PM EST - 4 months ago

CAMP4 to Participate in Upcoming Investor Conferences

Mar 5, 2026, 4:05 PM EST - 4 months ago

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 5, 2026, 7:00 AM EST - 4 months ago

Camp4 Therapeutics Annual report: Q4 2025

Mar 5, 2026, 6:00 AM EST - 4 months ago

Camp4 Therapeutics Slides: Corporate presentation

2026-02-19T15:50:18.000Z - 5 months ago

Camp4 Therapeutics participates in a conf call hosted by Cantor Fitzgerald

Jan 14, 2026, 6:45 PM EST - 6 months ago

Camp4 Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 6 months ago

Camp4 Therapeutics Slides: Corporate presentation

Jan 6, 2026, 8:00 AM EST - 6 months ago

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-18T12:21:08.000Z - 7 months ago

Camp4 Therapeutics prices 5M shares at $6.00 in underwritten public offering

2025-12-18T12:16:54.000Z - 7 months ago

Camp4 Therapeutics 5M share Secondary priced at $6.00

2025-12-18T12:11:53.000Z - 7 months ago

Camp4 Therapeutics, GSK enter strategic collaboration

GSK

Dec 18, 2025, 7:10 AM EST - 7 months ago

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

Dec 18, 2025, 7:00 AM EST - 7 months ago

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

2025-12-12T16:05:39.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

2025-12-11T16:45:34.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO

Dec 3, 2025, 4:00 PM EST - 7 months ago

Camp4 Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 8 months ago

Camp4 Therapeutics Registration statement: Registration filing

Nov 6, 2025, 4:05 PM EST - 8 months ago

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 5, 2025, 6:00 PM EST - 8 months ago

Camp4 Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 8 months ago

Camp4 Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 7:00 AM EST - 9 months ago

Camp4 Therapeutics Registration statement: Registration filing

Oct 21, 2025, 12:00 PM EDT - 9 months ago

Camp4 Therapeutics Transcript: Chardan's 9th Annual Genetic Medicines Conference

2025-10-02T10:46:18.000Z - 10 months ago

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-02T10:40:11.000Z - 10 months ago

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-01T12:10:16.000Z - 10 months ago

Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01

Oct 1, 2025, 8:00 AM EDT - 10 months ago

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

2025-09-16T09:30:08.000Z - 10 months ago

Camp4 Therapeutics downgraded to Neutral from Overweight at JPMorgan

2025-09-15T10:20:08.000Z - 10 months ago

Camp4 Therapeutics price target lowered to $12 from $18 at Piper Sandler

Sep 10, 2025, 7:00 AM EDT - 10 months ago

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Aug 14, 2025, 4:05 PM EDT - 11 months ago

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 13, 2025, 6:00 PM EDT - 11 months ago

Camp4 Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 6:00 PM EDT - 11 months ago

Camp4 Therapeutics Earnings release: Q2 2025

May 16, 2025, 6:00 AM EDT - 1 year ago

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 4:05 PM EDT - 1 year ago

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

May 13, 2025, 12:00 AM EDT - 1 year ago

Camp4 Therapeutics Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Camp4 Therapeutics Earnings release: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Mar 27, 2025, 4:05 PM EDT - 1 year ago

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Camp4 Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Camp4 Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Mar 13, 2025, 10:39 PM EDT - 1 year ago

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 2:58 PM EDT - 1 year ago

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 10, 2025, 4:20 PM EDT - 1 year ago

Camp4 Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Feb 12, 2025, 10:00 AM EST - 1 year ago

Camp4 Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Camp4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 6:45 PM EST - 1 year ago

Camp4 Therapeutics Slides: 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Dec 5, 2024, 1:00 PM EST - 1 year ago

Camp4 Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 7:00 AM EST - 1 year ago

Camp4 Therapeutics Quarterly report: Q3 2024

Nov 21, 2024, 7:00 AM EST - 1 year ago

Camp4 Therapeutics Earnings release: Q3 2024

Oct 10, 2024, 7:07 PM EDT - 1 year ago

CAMP4 Announces Pricing of Initial Public Offering

TigrePeidando Jul. 9 at 3:57 PM

0 · Reply

5G_C Jul. 9 at 1:26 PM

0 · Reply

5G_C Jul. 9 at 11:15 AM

$CAMP $NVDA partnership to be announced later this month 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

5G_C Jul. 9 at 11:09 AM

$NVDA $CAMP

0 · Reply

TigrePeidando Jul. 9 at 11:05 AM

0 · Reply

ZinoStonks Jul. 9 at 3:10 AM

1 · Reply

Revicta Jul. 2 at 2:37 AM

$CAMP consolidating back to $4

0 · Reply

TigrePeidando Jul. 1 at 2:05 PM

$CAMP Feels like something great is going to happen soon 🚀🚀🚀🚀

0 · Reply

Revicta Jun. 29 at 1:25 PM

$CAMP today we may push to $5++++

0 · Reply

5G_C Jun. 29 at 9:50 AM

$NVDA could partner with $CAMP to expand its AI medicine tools. Buying more now, should see $20+ within the next couple of months! 🚀 📈

0 · Reply

5G_C Jun. 29 at 9:35 AM

$CAMP is evolving from a small-cap biotech into what could become a first of its kind AI-powered precision medicine platform. When the Anthropic angle becomes reality, the news will cause the stock to 30x. Add an extended cash runway through 2038, advancing SYNGAP1 clinical progress, and a differentiated regulatory RNA platform, and earnings suddenly become a major catalyst. Positive clinical data, new partnerships, and AI-related announcements could ignite significant momentum. $10–15 could arrive quickly, with $20+ possible if multiple catalysts align!

1 · Reply

TigrePeidando Jun. 26 at 9:53 PM

$CAMP I think we will see another run up to $5 on Monday. Keep buying 🚀

2 · Reply

TigrePeidando Jun. 25 at 11:28 PM

$CAMP Just scooped more shares on the light pullback because when the fundamentals are this stacked, volatility is just noise in the matrix. We’re talking RAP platform + EPIC AI model delivering real-time target ID advantages, validated by that massive GSK collaboration ($17.5M upfront + milestone rocket fuel). Layer on the Anthropic strategic buzz and potential acquisition tailwinds, plus accelerating SYN GAP1 progress... this isn’t just another biotech play. This is convergent AI-biotech infrastructure hitting escape velocity. The AI adoption curve is about to go parabolic as partnerships color the roadmap and enterprise integration accelerates. New near-term target: $20–$30.

1 · Reply

Revicta Jun. 25 at 4:32 PM

$CAMP Add in the RAP platform + EPIC AI model that’s actually delivering real target ID advantages, the GSK collab validation ($17.5M upfront + massive milestones), and the rumored strategic angles (Anthropic buzz + potential acquisitions)… this thing is severely undervalued at these levels.

1 · Reply

TigrePeidando Jun. 25 at 2:23 AM

More signs of AI adoption for $CAMP as the company continues integrating AI into its therapeutic medicine platform. If the rumored Anthropic connection turns into a formal partnership, it will run to $10+. There are also discussions around potential strategic acquisitions, which could provide another meaningful catalyst. At these levels, I'm continuing to buy and add to my position. I don't think these prices will last much longer. In my opinion, this stock is severely undervalued, and I believe it could make a strong move soon.

0 · Reply

TigrePeidando Jun. 22 at 7:27 PM

More signs of AI adoption for $CAMP as the company further integrates AI into its therapeutic medicine platform. If the rumored Anthropic connection turns into a deal, the market could significantly re-rate this stock. At these levels, I think it is severely undervalued. Price target: $10+.

0 · Reply

MadStockAlerts1 Jun. 18 at 12:24 PM

Premarket top gainers $BEEM +18.7% ($1.40) $LASE +17.8% ($2.32) $AHMA +16.1% ($2.24) $PURR +13.9% ($10.64) $CAMP +13.4% ($4.49)

0 · Reply

Slingshot Jun. 16 at 1:40 PM

$CAMP JP Morgan bio pump 👈

0 · Reply

topstockalerts Jun. 16 at 12:08 PM

$CAMP interesting how little resistance there is

0 · Reply

notreload_ai Jun. 16 at 10:30 AM

JPMorgan upgrades $CAMP to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results. https://notreload.xyz/xy/jpmorgan-sees-127-upside-in-camp-as-it-upgrades-to-overweight-on-cmp-002-potential/

0 · Reply

Toptradersam Jun. 16 at 8:58 AM

$NBIS $HUBC $PURR $CAMP $STI The opportunity here could be massive. Strong growth potential, exciting catalysts, and a chart worth watching closely. 📈 https://www.youtube.com/watch?v=B3HnuvVPU-g

1 · Reply

TigrePeidando Jun. 16 at 8:44 AM

$CAMP Moving towards ai adoption and could be first biotech firm with actual use case.

0 · Reply

Market Cap	233.67M
Revenue (ttm)	3.50M
Net Income (ttm)	-80.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,297.14%
Debt to Equity Ratio	0.00

Volume	164,400
Avg Vol	194,370
Day's Range	N/A - N/A
Shares Out	51.93M
Stochastic %K	63%
Beta	0.10
Analysts	Strong Sell
Price Target	$8.36